GlassScriptPhysician profile
Urvi Pradeep Vyas
NPI 1730477142
$1,492.99
in general payments reported to CMS, 2019-2025
26 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $11.56 · 2021: $248 · 2022: $409 · 2023: $459 · 2024: $80.98 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.82 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $232.55 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $157.98 | 2019-2025 | Evenity |
| Abbott Laboratories | $146.32 | 2021-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2022 | |
| Novo Nordisk INC | $124.01 | 2021-2025 | Sogroya |
| Dexcom, INC. | $89.91 | 2021-2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $68.94 | 2022-2023 | Tepezza |
| Medtronic Minimed, INC. | $57.86 | 2019 | |
| Medtronic, INC. | $52.27 | 2021-2022 | |
| Corcept Therapeutics | $49.40 | 2023 | Korlym |
| Radius Health, INC. | $47.65 | 2023 | |
| Xeris Pharmaceuticals, INC. | $46.86 | 2022-2024 | Gvoke Hypopen |
| Mannkind Corporation | $42.50 | 2025 | |
| Abbvie INC. | $35.29 | 2021-2024 | |
| Insulet Corporation | $33.76 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.16 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $24.76 | 2023 | Jynarque |
| Gilead Sciences, INC. | $21.30 | 2019 | |
| Merck Sharp & Dohme LLC | $18.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.20 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $15.87 | 2022 | |
| Boston Scientific Corporation | $13.52 | 2023 | Watchman Flx |
| Esperion Therapeutics, INC. | $12.70 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.49 | 2021 | |
| Dynavax Technologies Corporation | $11.56 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.16 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Urvi Vyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.